Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

View Full Paper
Ask AI
Bookmark
Share

Authors

CDCatherine DiefenbachDMDipenkumar ModiWSWaleed Sabry

Discussion

Loading...

Member takes

Overview

Phase Ib/II trial shows durable complete response in large B-cell lymphoma patients, indicating potential treatment benefits.

Key Points

  • To evaluate the long-term efficacy and safety of mosunetuzumab and polatuzumab vedotin in patients with large B-cell lymphoma.
  • Phase Ib/II clinical trial with patients having relapsed or refractory large B-cell lymphoma
  • Patients received fixed-duration intravenous therapy of mosunetuzumab and polatuzumab vedotin
  • Endpoints focused on overall response rate, complete response rate, and safety assessments.
  • Overall response rate was 62% and complete response rate was 50% after three years
  • Median progression-free survival was 14.1 months, indicating potential long-term benefits
  • Safety profile remained manageable during the follow-up period.

Cite This Study

Diefenbach et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dee4https://doi.org/10.1182/blood-2025-3735
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).2024 · 2 citations
  2. 2Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma2025
  3. 3Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma2025
  4. 4A Randomized Phase <scp>II</scp> Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma2026 · 1 citations
  5. 5Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations